Tower Research Capital LLC (Trc) C4 Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 23,696 shares of CCCC stock, worth $96,205. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,696
Previous 21,844
8.48%
Holding current value
$96,205
Previous $100,000
35.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CCCC
# of Institutions
130Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$27.9 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$26.8 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$23.1 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$19.8 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$18.5 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $199M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...